Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
出版年份 2021 全文链接
标题
Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
作者
关键词
-
出版物
Cancers
Volume 13, Issue 2, Pages 334
出版商
MDPI AG
发表日期
2021-01-19
DOI
10.3390/cancers13020334
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Revisiting Immunotherapy: A Focus on Prostate Cancer
- (2020) Ha-Ram Cha et al. CANCER RESEARCH
- Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study
- (2020) Wassim Abida et al. CLINICAL CANCER RESEARCH
- pVACtools: a computational toolkit to identify and visualize cancer neoantigens
- (2020) Jasreet Hundal et al. Cancer Immunology Research
- PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models
- (2020) Takahiro Yamazaki et al. OncoImmunology
- Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: Results of cohort 6 of the COSMIC-021 study.
- (2020) Neeraj Agarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I/II study of GB1275, a first-in-class oral CD11b modulator, alone, and combined with pembrolizumab in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (KEYNOTE-A36).
- (2020) Drew W. Rasco et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer
- (2020) Sumit K. Subudhi et al. Science Translational Medicine
- Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
- (2020) Adi Diab et al. Cancer Discovery
- Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies
- (2020) Jason Cham et al. Journal for ImmunoTherapy of Cancer
- A genetic vaccine encoding shared cancer neoantigens to treat tumors with Microsatellite Instability.
- (2020) Guido Leoni et al. CANCER RESEARCH
- Multicenter Phase 1 Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
- (2020) Christos E. Kyriakopoulos et al. CLINICAL CANCER RESEARCH
- An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
- (2020) Ugur Sahin et al. NATURE
- Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial
- (2020) Federica Cappuccini et al. Journal for ImmunoTherapy of Cancer
- Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA
- (2020) Pedro Barata et al. Journal for ImmunoTherapy of Cancer
- Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial
- (2020) Padmanee Sharma et al. CANCER CELL
- Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors
- (2020) Karim Fizazi et al. EUROPEAN UROLOGY
- Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis
- (2020) Junru Chen et al. Frontiers in Oncology
- Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
- (2020) Rilan Bai et al. Biomarker Research
- A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours
- (2020) Mark T. J. van Bussel et al. BRITISH JOURNAL OF CANCER
- Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
- (2019) Xianjie Jiang et al. Molecular Cancer
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
- (2019) Shuang Qin et al. Journal of Hematology & Oncology
- Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
- (2019) James L. Gulley et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequential therapy with ramucirumab and/or checkpoint inhibitors for non-small-cell lung cancer in routine practice
- (2019) Cliff Molife et al. Future Oncology
- First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors
- (2019) Olivier Bylicki et al. BIODRUGS
- An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer
- (2019) Steven Feins et al. AMERICAN JOURNAL OF HEMATOLOGY
- Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
- (2019) Marilina García-Aranda et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
- (2019) André F. Oliveira et al. Frontiers in Oncology
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications
- (2019) Yuxin Lin et al. Journal of Hematology & Oncology
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression
- (2019) Sherly Mardiana et al. Science Translational Medicine
- Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies
- (2019) Roheena Z. Panni et al. Science Translational Medicine
- Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T Cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms
- (2019) Cansu Cimen Bozkus et al. Cancer Discovery
- Targeted APC Activation in Cancer Immunotherapy to Enhance the Abscopal Effect
- (2019) Nathan Suek et al. Frontiers in Immunology
- Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
- (2019) Alessandro Leonetti et al. DRUG RESISTANCE UPDATES
- Prospects for combining immune checkpoint blockade with PARP inhibition
- (2019) Anping Li et al. Journal of Hematology & Oncology
- Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
- (2019) Meenal Sharma et al. MEDICINE
- Neoantigen vaccine: an emerging tumor immunotherapy
- (2019) Miao Peng et al. Molecular Cancer
- Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
- (2019) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications
- (2019) Matthew J. Ryan et al. Frontiers in Oncology
- Peptide-Based Vaccines: Current Progress and Future Challenges
- (2019) Ryan J. Malonis et al. CHEMICAL REVIEWS
- Phase II Trial of a DNA Vaccine Encoding Prostatic Acid Phosphatase (pTVG-HP [MVI-816]) in Patients With Progressive, Nonmetastatic, Castration-Sensitive Prostate Cancer
- (2019) Douglas G. McNeel et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
- (2018) A R Hansen et al. ANNALS OF ONCOLOGY
- Defective HLA class I antigen processing machinery in cancer
- (2018) Lei Cai et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies
- (2018) Gwenaelle Gravis et al. EUROPEAN UROLOGY
- Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Michael J. Morris et al. JOURNAL OF CLINICAL ONCOLOGY
- mRNA vaccines — a new era in vaccinology
- (2018) Norbert Pardi et al. NATURE REVIEWS DRUG DISCOVERY
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
- (2018) Michael R. Migden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer
- (2018) Karim Boudadi et al. Oncotarget
- Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer
- (2018) Yong Joong Kim et al. CLINICAL NUCLEAR MEDICINE
- VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer.
- (2018) Irina Redchenko et al. JOURNAL OF CLINICAL ONCOLOGY
- An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD).
- (2018) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II neoadjuvant and immunologic study of B7-H3 targeting with enoblituzumab in localized intermediate- and high-risk prostate cancer.
- (2018) Eugene Shenderov et al. JOURNAL OF CLINICAL ONCOLOGY
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- New Vaccine Technologies to Combat Outbreak Situations
- (2018) Susanne Rauch et al. Frontiers in Immunology
- A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours
- (2018) Amit Maity et al. BRITISH JOURNAL OF CANCER
- Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression
- (2018) Bing Song et al. JOURNAL OF CLINICAL INVESTIGATION
- Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
- (2018) Derin B. Keskin et al. NATURE
- MDSC; the Most Important Cell You Have Never Heard Of
- (2018) R.J. Tesi TRENDS IN PHARMACOLOGICAL SCIENCES
- Integrin CD11b activation drives anti-tumor innate immunity
- (2018) Michael C. Schmid et al. Nature Communications
- High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
- (2018) Saman Maleki Vareki Journal for ImmunoTherapy of Cancer
- Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer
- (2017) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
- (2017) Tomasz M. Beer et al. JOURNAL OF CLINICAL ONCOLOGY
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
- (2017) Narek Shaverdian et al. LANCET ONCOLOGY
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- (2017) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
- (2017) Nicholas D. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer
- (2017) Kenji Gonda et al. Oncology Letters
- Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities
- (2017) An-Liang Xia et al. Oncotarget
- 5T4 oncofoetal antigen: an attractive target for immune intervention in cancer
- (2016) Peter L. Stern et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Dendritic cell-based immunotherapy
- (2016) Rachel L Sabado et al. CELL RESEARCH
- PARP inhibitor combination therapy
- (2016) Amy Dréan et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Harnessing T cells to fight cancer with BiTE®antibody constructs - past developments and future directions
- (2016) Matthias Klinger et al. IMMUNOLOGICAL REVIEWS
- Association of ARV7 expression with molecular and clinical characteristics in prostate cancer.
- (2016) Himanshu Joshi et al. JOURNAL OF CLINICAL ONCOLOGY
- Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
- (2016) Lena M. Kranz et al. NATURE
- A second chance for telomerase reverse transcriptase in anticancer immunotherapy
- (2016) Maurizio Zanetti Nature Reviews Clinical Oncology
- Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis
- (2016) B Benzon et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors
- (2016) Bing-Lan Zhang et al. Science China-Life Sciences
- Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse
- (2016) Yang Pu et al. Science Translational Medicine
- Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer
- (2016) Julie N. Graff et al. Oncotarget
- The Role of TAM Family Receptors in Immune Cell Function: Implications for Cancer Therapy
- (2016) Magdalena Paolino et al. Cancers
- Persistent Neutrophil to Lymphocyte Ratio >3 during Treatment with Enzalutamide and Clinical Outcome in Patients with Castration-Resistant Prostate Cancer
- (2016) Vincenza Conteduca et al. PLoS One
- The Role of Myeloid-Derived Suppressor Cells in Patients with Solid Tumors: A Meta-Analysis
- (2016) Shuo Zhang et al. PLoS One
- The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1 −/− murine model of ovarian cancer
- (2015) Jing Huang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
- (2015) Kathleen M. Mahoney et al. CLINICAL THERAPEUTICS
- Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer
- (2015) Julia Stieglmaier et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Novel Roles of c-Met in the Survival of Renal Cancer Cells through the Regulation of HO-1 and PD-L1 Expression
- (2015) Murugabaskar Balan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Unfolding the Mutational Landscape of Human Melanoma
- (2015) Diwakar Davar et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- In silico analyses of Wilms׳ tumor protein to designing a novel multi-epitope DNA vaccine against cancer
- (2015) Saeed Khalili et al. JOURNAL OF THEORETICAL BIOLOGY
- Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
- (2015) Andrew B Sharabi et al. LANCET ONCOLOGY
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
- (2015) Christopher J. Sweeney et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis
- (2015) Francesco Massari et al. Targeted Oncology
- Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses
- (2015) Paul A. Beavis et al. Cancer Immunology Research
- The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
- (2015) Leisha A. Emens et al. Cancer Immunology Research
- CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
- (2015) T. Higuchi et al. Cancer Immunology Research
- HIF-1α pathway: role, regulation and intervention for cancer therapy
- (2015) Georgina N. Masoud et al. Acta Pharmaceutica Sinica B
- Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
- (2015) Patrick A. Ott et al. Frontiers in Oncology
- PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
- (2015) Jennifer L. Bishop et al. Oncotarget
- Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
- (2014) S. J. Dovedi et al. CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Pten Null Prostate Epithelium Promotes Localized Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Tumor Initiation and Progression
- (2014) A. J. Garcia et al. MOLECULAR AND CELLULAR BIOLOGY
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
- (2014) A. B. Sharabi et al. Cancer Immunology Research
- Relapse or Eradication of Cancer Is Predicted by Peptide-Major Histocompatibility Complex Affinity
- (2013) Boris Engels et al. CANCER CELL
- Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
- (2013) Thomas F Gajewski et al. CURRENT OPINION IN IMMUNOLOGY
- Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis
- (2013) Gang Liu et al. JOURNAL OF CLINICAL INVESTIGATION
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
- (2013) Paul F Robbins et al. NATURE MEDICINE
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- A2B adenosine receptor blockade inhibits growth of prostate cancer cells
- (2013) Qiang Wei et al. Purinergic Signalling
- Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial
- (2013) Paul F. Schellhammer et al. UROLOGY
- Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
- (2012) Douglas Hanahan et al. CANCER CELL
- The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer
- (2012) Brian M. Olson et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine
- (2012) Masanori Noguchi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity
- (2012) Timothy S. Fisher et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer
- (2012) Anna Flammiger et al. EUROPEAN JOURNAL OF CANCER
- Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation
- (2012) A. Gupta et al. JOURNAL OF IMMUNOLOGY
- Improved Overall Survival Trends of Men with Newly Diagnosed M1 Prostate Cancer: A SWOG Phase III Trial Experience (S8494, S8894 and S9346)
- (2012) Catherine M. Tangen et al. JOURNAL OF UROLOGY
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Alfons JM van den Eertwegh et al. LANCET ONCOLOGY
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- The mutational landscape of lethal castration-resistant prostate cancer
- (2012) Catherine S. Grasso et al. NATURE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-Associated Antigens for Specific Immunotherapy of Prostate Cancer
- (2012) Andrea Kiessling et al. Cancers
- Delineation of a Cellular Hierarchy in Lung Cancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells
- (2011) M. Damelin et al. CANCER RESEARCH
- Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
- (2011) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation
- (2011) Wei Liao et al. CURRENT OPINION IN IMMUNOLOGY
- Waif1/5T4 Inhibits Wnt/β-Catenin Signaling and Activates Noncanonical Wnt Pathways by Modifying LRP6 Subcellular Localization
- (2011) Birgit Kagermeier-Schenk et al. DEVELOPMENTAL CELL
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients
- (2010) Olivier Adotevi et al. JOURNAL OF IMMUNOTHERAPY
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- CXCR4 Mediated Chemotaxis Is Regulated by 5T4 Oncofetal Glycoprotein in Mouse Embryonic Cells
- (2010) Thomas D. Southgate et al. PLoS One
- Drug safety is a barrier to the discovery and development of new androgen receptor antagonists
- (2010) William R. Foster et al. PROSTATE
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
- (2009) Celestia S. Higano et al. CANCER
- Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
- (2009) J. S. Ko et al. CLINICAL CANCER RESEARCH
- Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer
- (2009) Ravi A Madan et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The significance of OX40 and OX40L to T-cell biology and immune disease
- (2009) Michael Croft et al. IMMUNOLOGICAL REVIEWS
- Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage D0 Prostate Cancer
- (2009) Douglas G. McNeel et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients
- (2009) Philippe O. Gannon et al. JOURNAL OF IMMUNOLOGICAL METHODS
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Viral vectors: from virology to transgene expression
- (2008) D Bouard et al. BRITISH JOURNAL OF PHARMACOLOGY
- Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
- (2008) Celestia S. Higano et al. CANCER
- HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance
- (2008) M Campoli et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search